Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kazuo Nishimura

Showing results (81-90 of 189) with videos related to

Pageof 19
Sort By:
Japanese Journal of Clinical Oncology|December 10, 2009
Tumor multiplicity is an independent prognostic factor of non-muscle-invasive high-grade (T1G3) bladder cancerYasutomo Nakai, Norio Nonomura, Atsunari Kawashima, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 8, 2009
Surveillance following orchiectomy for stage I testicular seminoma: long-term outcomeTakahiro Yoshida, Ken-ichi Kakimoto, Kentaro Takezawa, et al.
International Journal of Cancer|February 22, 2002
Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosisSompol Permpongkosol, Jing-Ding Wang, Shiro Takahara, et al.
International Journal of Clinical Oncology|September 3, 2020
Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastasesYoshiyuki Yamamoto, Yohei Okuda, Tomohiro Kanaki, et al.
IJU Case Reports|November 9, 2020
Advanced adrenocortical carcinoma successfully treated with gemcitabine plus capecitabine as second-line chemotherapyAkinaru Yamamoto, Yasutomo Nakai, Toshiki Oka, et al.
Japanese Journal of Clinical Oncology|November 9, 2014
A single-center study on predicting outcomes of primary androgen deprivation therapy for prostate cancer using the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) scoreYuichiro Yamaguchi, Yujiro Hayashi, Yu Ishizuya, et al.
Cancer Science|April 24, 2009
Vascular endothelial growth factor receptor 1 expression in pelvic lymph nodes predicts the risk of cancer progression after radical prostatectomyKazutoshi Fujita, Masashi Nakayama, Yasutomo Nakai, et al.
International Journal of Cancer|February 10, 2007
Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaBDaizo Oka, Kazuo Nishimura, Masahiro Shiba, et al.
International Journal of Clinical Oncology|June 21, 2012
Genetic polymorphisms of CYP17A1 in steroidogenesis pathway are associated with risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapyTakeshi Yamada, Masashi Nakayama, Tomohito Shimizu, et al.
International Journal of Clinical Oncology|July 14, 2025
Trends in real-world outcomes of patients with metastatic renal cell cancer in the recent treatment era: a single-institution analysisYasutomo Nakai, Shunki Nakagawa, Yutaka Kurahashi, et al.
Pageof 19

Showing results (81-90 of 189) with videos related to

Sort By:
Pageof 19
Japanese Journal of Clinical Oncology|December 10, 2009
Tumor multiplicity is an independent prognostic factor of non-muscle-invasive high-grade (T1G3) bladder cancerYasutomo Nakai, Norio Nonomura, Atsunari Kawashima, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 8, 2009
Surveillance following orchiectomy for stage I testicular seminoma: long-term outcomeTakahiro Yoshida, Ken-ichi Kakimoto, Kentaro Takezawa, et al.
International Journal of Cancer|February 22, 2002
Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosisSompol Permpongkosol, Jing-Ding Wang, Shiro Takahara, et al.
International Journal of Clinical Oncology|September 3, 2020
Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastasesYoshiyuki Yamamoto, Yohei Okuda, Tomohiro Kanaki, et al.
IJU Case Reports|November 9, 2020
Advanced adrenocortical carcinoma successfully treated with gemcitabine plus capecitabine as second-line chemotherapyAkinaru Yamamoto, Yasutomo Nakai, Toshiki Oka, et al.
Japanese Journal of Clinical Oncology|November 9, 2014
A single-center study on predicting outcomes of primary androgen deprivation therapy for prostate cancer using the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) scoreYuichiro Yamaguchi, Yujiro Hayashi, Yu Ishizuya, et al.
Cancer Science|April 24, 2009
Vascular endothelial growth factor receptor 1 expression in pelvic lymph nodes predicts the risk of cancer progression after radical prostatectomyKazutoshi Fujita, Masashi Nakayama, Yasutomo Nakai, et al.
International Journal of Cancer|February 10, 2007
Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaBDaizo Oka, Kazuo Nishimura, Masahiro Shiba, et al.
International Journal of Clinical Oncology|June 21, 2012
Genetic polymorphisms of CYP17A1 in steroidogenesis pathway are associated with risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapyTakeshi Yamada, Masashi Nakayama, Tomohito Shimizu, et al.
International Journal of Clinical Oncology|July 14, 2025
Trends in real-world outcomes of patients with metastatic renal cell cancer in the recent treatment era: a single-institution analysisYasutomo Nakai, Shunki Nakagawa, Yutaka Kurahashi, et al.
Pageof 19